06 November 2020 : Original article
Outcomes of Living-Donor Kidney Transplantation in Female Recipients with Possible Pregnancy-Related Pre-Sensitization According to Donor Relationship
Jee Yeon Kim1BCDEF, Mun Chae Choi2BCD, Dong Hyun Kim1BCD, Youngmin Ko1BCD, Seong Jun Lim1B, Joo Hee Jung1B, Hyunwook Kwon1BCD, Young Hoon Kim1ABE, Sung Shin1ABCDEF*, Duck Jong Han1ABEDOI: 10.12659/AOT.925229
Ann Transplant 2020; 25:e925229
Table 1 Baseline characteristics.
| Group I (Offspring to mother) (N=175) | Group II (Husband to wife) (N=159) | Group III (Other unrelated donor) (N=56) | P-value | |
|---|---|---|---|---|
| Mean age, y (SD) | 55.6±6.6 | 48.4±8.1 | 51.4±10.5 | <0.001 |
| Body mass index, kg/m (SD) | 23.3±3.4 | 21.7±3.3 | 22.3±3.1 | <0.001 |
| Duration of dialysis, months (SD) | 18.0±29.6 | 19.0±36.2 | 43.9±63.4 | 0.032 |
| Type of dialysis, n (%) | 0.839 | |||
| Hemodialysis | 113 (64.6) | 114 (71.7) | 37 (66.1) | |
| Peritoneal dialysis | 19 (10.9) | 15 (9.4) | 6 (10.7) | |
| Diabetes mellitus, n (%) | 45 (25.7) | 28 (17.6) | 10 (17.9) | 0.156 |
| Hypertension, n (%) | 156 (89.1) | 134 (84.3) | 44 (78.6) | 0.119 |
| Primary cause of ESRD, n (%) | 0.002 | |||
| Hypertension | 41 (23.4) | 22 (13.8) | 8 (14.3) | |
| Diabetes mellitus | 42 (24.0) | 29 (18.2) | 8 (14.3) | |
| Glomerulonephritis | 18 (10.3) | 11 (6.9) | 7 (12.5) | |
| IgA nephropathy | 21 (12.0) | 25 (15.7) | 5 (8.9) | |
| FSGS | 1 (0.6) | 5 (3.1) | 0 (0.0) | |
| Polycystic kidney disease | 4 (2.3) | 10 (6.3) | 4 (7.1) | |
| Unknown | 38 (21.7) | 44 (27.7) | 17 (30.4) | |
| Others | 10 (5.7) | 13 (8.2) | 7 (12.5) | |
| History of malignancy, n (%) | 10 (5.7) | 6 (3.8) | 6 (10.7) | 0.154 |
| Number of HLA mismatch (ABDR), (SD) | 2.4±0.9 | 4.4±1.2 | 4.5±1.2 | <0.001 |
| Number of HLA mismatch(DR), (SD) | 0.8±0.4 | 1.6±1.2 | 1.4±0.6 | <0.001 |
| Pre-transplant DSA, n (%) | 46 (31.1) | 45 (32.1) | 9 (20.5) | 0.318 |
| ABO incompatible KT, n (%) | 35 (20.0) | 54 (34.0) | 10 (17.9) | 0.005 |
| Immunosuppression | ||||
| Induction, n (%) | 0.033 | |||
| Basiliximab | 136 (91.9) | 129 (95.6) | 47 (97.9) | |
| Thymoglobulin | 4 (2.7) | 6 (4.4) | 0 (0.0) | |
| None | 8 (5.4) | 0 (0.0) | 1 (2.1) | |
| Calcineurin inhibitor, n (%) | 0.091 | |||
| Cyclosporine | 44 (31.0) | 26 (20.8) | 16 (34.0) | |
| Tacrolimus | 97 (68.3) | 99 (79.2) | 31 (66.0) | |
| Antimetabolite, n (%) | 0.681 | |||
| Mycophenolate mofetil | 85 (59.9) | 75 (59.5) | 30 (63.8) | |
| Myfortic acid | 48 (33.8) | 40 (31.7) | 14 (29.8) | |
| Azathioprine | 5 (3.5) | 2 (1.6) | 1 (2.1) | |
| Cyclophosphamide | 0 (0.0) | 2 (1.6) | 0 (0.0) | |
| None | 4 (2.8) | 7 (5.6) | 2 (4.3) | |
| Steroid, n (%) | 0.945 | |||
| Maintenance | 139 (97.9) | 124 (98.4) | 46 (97.9) | |
| Steroid withdrawal | 3 (2.1) | 2 (1.6) | 1 (2.1) | |
| Mean age, y (SD) | 29.5±7.5 | 49.0±8.6 | 42.9±9.0 | <0.001 |
| Body mass index, kg/m (SD) | 23.2±4.2 | 24.5±2.0 | 23.4±2.7 | 0.307 |
| Cold ischemic time, min (SD) | 42.4±22.7 | 46.8±30.6 | 42.6±20.7 | 0.910 |
| 24-h creatinine clearance, mL/min (SD) | 125.2±29.2 | 121.9±28.1 | 112.2±26.7 | 0.037 |
| 24-h urine protein, mg/day (SD) | 78.1±22.6 | 91.2±28.7 | 86.9±30.7 | 0.003 |
| Serum creatinine (SD) | 0.81±0.16 | 0.91±0.12 | 0.78±0.15 | <0.001 |
| HbA1c (SD) | 5.4±0.2 | 5.5±0.3 | 5.2±0.2 | 0.104 |
| Hospitalization duration, day (SD) | 14.6±11.7 | 16.4±11.5 | 16.0±8.3 | 0.072 |
| SD – standard deviation; ESRD – end-stage renal disease; FSGS – focal segmental glomerulosclerosis; HLA – human leukocyte antigen; DSA – donor-specific antibody; KT – kidney transplantation; eGFR – estimated glomerular filtration rate; CKD-EPI – Chronic Kidney Disease Epidemiology Collaboration. | ||||